Taku Kamei

USPTO Granted Patents = 13 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 7.8

ph-index = 4

Forward Citations = 41(Granted Patents)

Location History:

Kamakura, JP (2022)
Osaka, JP (2013 - 2023)
Kanagawa, JP (2014 - 2023)
Fujisawa, JP (2018 - 2024)

Company Filing History:

12 out of 1,179

Takeda Pharmaceutical Company Limited

patents

1 out of 712

The Rockefeller University

patents

Years Active: 2013-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11952344 - Heterocyclic compound and use thereof (2024-04-09),

2. RE49686 - Nitrogen-containing heterocyclic compound and use of same (2023-10-10),

3. 11713311 - Heterocyclic compound (2023-08-01),

4. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

5. 11414422 - Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS (2022-08-16),

6. 11230541 - Heterocyclic compound (2022-01-25),

7. RE48334 - Nitrogen-containing heterocyclic compound and use of same (2020-11-30),

8. 10807987 - Heterocyclic compound and use thereof (2020-10-20),

9. 10131653 - Heterocyclic compound (2018-11-20),

10. 9187453 - Heterocyclic compound (2015-11-17),

11. 8722662 - Heterocyclic compounds (2014-05-13),

12. 8592454 - Nitrogen-containing heterocyclic compound and use of same (2013-11-26),

13. 8470816 - Nitrogen-containing heterocyclic compound and use thereof (2013-06-25),

Title: Taku Kamei: Innovator in Heterocyclic Compounds

Introduction

Taku Kamei is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of heterocyclic compounds. With a total of 13 patents to his name, Kamei's work is recognized for its potential therapeutic applications.

Latest Patents

Among his latest patents is a heterocyclic compound that exhibits antagonistic action on an NMDA receptor containing the NR2B subunit. This compound is expected to be useful as a prophylactic or therapeutic agent for various conditions, including depression, bipolar disorder, migraine, pain, and peripheral symptoms of dementia. Another notable patent involves a nitrogen-containing heterocyclic compound, which is represented by a specific formula. This invention highlights the versatility of heterocycles in medicinal applications.

Career Highlights

Kamei has worked with esteemed organizations such as Takeda Pharmaceutical Company Limited and The Rockefeller University. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative therapeutic agents.

Collaborations

Some of his notable coworkers include Norihito Tokunaga and Yuya Oguro. Their collaborative efforts have further enriched the research environment and fostered innovation in their respective fields.

Conclusion

Taku Kamei's contributions to the field of heterocyclic compounds demonstrate his commitment to advancing medical science. His innovative patents and collaborations reflect a dedication to improving therapeutic options for various health conditions.

This text is generated by artificial intelligence and may not be accurate.